Feb 10, 2022 / 03:30PM GMT
Charles Zhu - Guggenheim Partners - Analyst
Hello, everyone, and welcome back. I am Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with Merus, a clinical-stage oncology biotech with a bispecific antibody platform. Joining us is CEO, Bill Lundberg.
Bill, I want to say thank you very much for your time this morning. We really appreciate it, and we are really happy to have you on board. Perhaps, before we jump into Q&A, would you be able to provide us just a two- to three-minute overview of Merus's pipeline platform as well as some of your particular assets?
Bill Lundberg - Merus N.V. - President, CEO, Principal Financial Officer, & Executive Director
Yeah. First, let me thank you, Charles, for your support and the opportunity to speak and share the fireside chat with you today. And thanks to the support from the entire Guggenheim team. It's really helpful.
Merus is a bispecific or multispecific antibody company focused on therapies for cancer. And our whole platform is based
Merus NV at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers